BACKGROUND: Using killed microorganisms or their parts to stimulate immunity for cancer treatment dates back to the end of 19th century. Since then, it undergone considerable development. Our novel approach binds ligands to the tumor cell surface, which stimulates tumor phagocytosis. The therapeutic effect is further amplified by simultaneous application of agonists of Toll-like receptors. We searched for ligands that induce both a strong therapeutic effect and are safe for humans. METHODS: B16-F10 murine melanoma model was used. For the stimulation of phagocytosis, mannan or N-formyl-methionyl-leucyl-phenylalanine, was covalently bound to tumor cells or attached using hydrophobic anchor. The following agonists of Toll-like receptors were studied: monophosphoryl lipid A (MPLA), imiquimod (R-837), resiquimod (R-848), poly(I:C), and heat killed Listeria monocytogenes. RESULTS: R-848 proved to be the most suitable Toll-like receptor agonist for our novel immunotherapeutic approach. In combination with covalently bound mannan, R-848 significantly reduced tumor growth. Adding poly(I:C) and L. monocytogenes resulted in complete recovery in 83% of mice and in their protection from the re-transplantation of melanoma cells. CONCLUSION: An efficient cancer treatment results from the combination of Toll-like receptor agonists and phagocytosis stimulating ligands bound to the tumor cells.

1st Department of Internal Medicine Medical Faculty of P J Šafárik University in Košice Košice Slovakia

Department of Medical Biology Faculty of Science University of South Bohemia České Budějovice Czech Republic

Institute of Parasitology Biology Centre of the Czech Academy of Sciences v v i České Budějovice Czech Republic

University of Michigan Medical Center Ann Arbor MI USA

Zobrazit více v PubMed

Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci. 1893;10:487–511. doi: 10.1097/00000441-189305000-00001. PubMed DOI

Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552–9. doi: 10.1038/nm1589. PubMed DOI

Guha M. Anticancer TLR, agonists on the ropes. Nat Rev Drug Discov. 2012;11:503–5. doi: 10.1038/nrd3775. PubMed DOI

Janotová T, Jalovecká M, Auerová M, Švecová I, Bruzlová P, Maierová V, et al. The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model. PLoS One. 2014;9(1):e85222. doi: 10.1371/journal.pone.0085222. PubMed DOI PMC

Waldmannová E, Caisová V, Fáberová J, Sváčková P, Kovářová M, Sváčková D, et al. The use of Zymosan A and bacteria anchored to tumor cells for effective cancer immunotherapy: B16-F10 murine melanoma model. Int Immunopharmacol. 2016;39:295–306. doi: 10.1016/j.intimp.2016.08.004. PubMed DOI

Warren TS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B, et al. Resilience to bacterial infection: difference between species could be due to proteins in serum. J Infect Dis. 2010;201:223–32. doi: 10.1086/649557. PubMed DOI PMC

Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol. 2011;186(5):3248–57. doi: 10.4049/jimmunol.1002253. PubMed DOI

Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, et al. A novel glyco-conjugate valine against fungal pathogens. JEM. 2005;202:597–606. doi: 10.1084/jem.20050749. PubMed DOI PMC

Kato K, Itoh C, Yasukouchi T, Nagamune T. Rapid protein anchoring into the membranes of mammalian cells using oleyl chain and poly(etylene glycol) derivatives. Biotechnol Prog. 2004;20:897–904. doi: 10.1021/bp0342093. PubMed DOI

Christiaansen JF, Gallardo D, Burnside SS, Nelson AA, Sears DW. Rapid covalent coupling of proteins to cell surfaces: Immunological characterization of viable protein-cell conjugates. J Immunol Methods. 1984;74:229–39. doi: 10.1016/0022-1759(84)90290-4. PubMed DOI

Li J, Piao YF, Jiang Z, Chen L, Sun HB. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World J Gastroenterol. 2009;15:2602–8. doi: 10.3748/wjg.15.2602. PubMed DOI PMC

Stassen M, Valeva A, Walev I, Schmitt E. Activation of mast cells by streptolysin O and lipopolysaccharide. Methods Mol Biol. 2006;315:393–403. PubMed

Dewas C, Dang PM, Gougerot-Pocidalo MA, El-Benna J. TNF-alpha induces phosphorylation of p47phox in human neutrophils: Partial phosphorylation of p47phox is a common event of priming of human neutrophils by TNF-alpha and granulocyte-macrophage colony-stimulating factor. J Immunol. 2003;171:4392–8. doi: 10.4049/jimmunol.171.8.4392. PubMed DOI

Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. Rheumatology. 2010;49:1618–31. doi: 10.1093/rheumatology/keq045. PubMed DOI

Takayama K, Ribi E, Cantrell JL. Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res. 1981;41:2654–7. PubMed

Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosporyl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628–32. doi: 10.1126/science.1138963. PubMed DOI

Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008;13(8):859–75. doi: 10.1634/theoncologist.2008-0097. PubMed DOI

Schőn MP, Schőn M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27:190–9. doi: 10.1038/sj.onc.1210913. PubMed DOI

Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, et al. Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res. 2011;71(15):5123–33. doi: 10.1158/0008-5472.CAN-10-3903. PubMed DOI

Sato S, Takeuchi O, Fujito T, Tomizawa H, Takeda K, Akira S. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int Immunol. 2002;14:783–91. doi: 10.1093/intimm/dxf046. PubMed DOI

Tsukada K, Kitazawa T, Fukushima A, Okugawa S, Yanagimoto S, Tatsuno K, et al. Macrophage tolerance induced by stimulation with Toll-like receptor 7/8 ligands. Immunol Lett. 2007;111:51–6. doi: 10.1016/j.imlet.2007.05.001. PubMed DOI

Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol. 2011;11(7):879–89. doi: 10.1016/j.intimp.2010.12.024. PubMed DOI PMC

Lee M, Park CS, Lee YR, Im SA, Song S, Lee CK. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37(9):1234–40. doi: 10.1007/s12272-014-0379-4. PubMed DOI

Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102:2660–9. doi: 10.1182/blood-2003-04-1078. PubMed DOI

Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218:74–86. doi: 10.1016/S0008-8749(02)00517-8. PubMed DOI

Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol. 2000;203:55–65. doi: 10.1006/cimm.2000.1673. PubMed DOI

Zhang WW, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun. 2008;76:3777–83. doi: 10.1128/IAI.01527-07. PubMed DOI PMC

Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med. 2008;233(8):968–79. doi: 10.3181/0802-RM-58. PubMed DOI

Yeung VP, Gieni RS, Umetsu DT, DeKruyff RH. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol. 1998;161:4146–52. PubMed

Trinchieri G, Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179–90. doi: 10.1038/nri2038. PubMed DOI

Tan RST, Lin B, Liu Q, Tucker-Kellogg LT, Ho B, Leung BPL, Ding JL. The synergy in cytosine production through MyD88-TRIF pathways is co-ordinated with ERK phosphorylation in macrophages. Immunol Cell Biol. 2013;91:377–87. doi: 10.1038/icb.2012.54. PubMed DOI

Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJM, Brand A, Goulmy E. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163:57–61. PubMed

Tsujimoto H, Efron PA, Matsumoto T, Ungatro RF, Abouhamze A, Ono S, et al. Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA. Immunol Lett. 2006;107:155–62. doi: 10.1016/j.imlet.2006.09.001. PubMed DOI

Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M, Pouckova P, Suppl Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16. Cancer Chemother Pharmacol. 2001;47:16–22. doi: 10.1007/s002800170004. PubMed DOI

The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma

Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy

Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma

Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA)

The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40